Related Experiment Video
Updated: Sep 28, 2025
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.1K
CDK4/6 Inhibition Shows Clinical Activity in p16ink4A-Deficient Mesothelioma
Cancer Discovery
|April 4, 2022
Abstract:
Abemaciclib shows promising clinical activity in patients with relapsed, p16ink4A-deficient mesothelioma.
Insights
Abemaciclib demonstrates significant clinical activity in patients diagnosed with relapsed mesothelioma. This targeted therapy is particularly effective in cases where the tumor is deficient in p16INK4A protein.
Area of Science:
- Oncology
- Cancer Therapeutics
- Mesothelioma Research
Background:
- Malignant mesothelioma is an aggressive cancer with limited treatment options.
- The p16INK4A tumor suppressor gene is frequently lost or inactivated in mesothelioma.
- Identifying effective therapies for relapsed mesothelioma is a critical unmet need.
Purpose of the Study:
- To evaluate the clinical activity of abemaciclib in patients with relapsed mesothelioma.
- To investigate the role of p16INK4A deficiency in response to abemaciclib.
Main Methods:
- A clinical trial was conducted involving patients with relapsed mesothelioma.
- Patients received abemaciclib treatment.
- Tumor samples were assessed for p16INK4A expression.
Main Results:
- Abemaciclib treatment showed promising clinical activity in the patient cohort.
- A notable response was observed in patients with p16INK4A-deficient mesothelioma.
- Further analysis indicated a correlation between p16INK4A status and treatment efficacy.
Conclusions:
- Abemaciclib represents a potential therapeutic option for patients with relapsed mesothelioma.
- The p16INK4A deficiency may serve as a predictive biomarker for abemaciclib response.
- These findings warrant further investigation in larger clinical studies.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.9K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.4K
Related Concept Videos
02:34Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
02:15M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
02:23Abnormal Proliferation
4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
02:39Positive Regulator Molecules
5.7K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
02:38Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K